title: [Probiotics and children: is an integration useful in allergic diseases?].
abstract: Recent studies report that some probiotic strains are able to improve allergic diseases. For this reason, we would verify tolerability and efficacy of a industrial preparation of Lactobacillus paracasei (11,688; Proge Farm, Italy) and Lactobacillus salivarius (11,794; Proge Farm, Italy) and value their "in vitro" immunomodulatory effect. We know that, after birth, there's a persistence of Th2 immune response that predisposes to atopy, whereas commensal bacteria are able to induce a Th1 immune response that counter-balances the original response. The "in vivo" study was set up with the recruitment of 20 atopic pediatric patients treated 30 days with 2 doses of Fiorilac (Sharper, Italy), a preparation of the two strains in the proportion of 1:12. Only one patient referred significant improvements of atopic disease, 19 patients reported a good tolerability to the product and 3 patients had a regularization of intestinal function. Immunological tests showed an increase of Th1 immune response as in CD4+ lymphocytes percentage as of IL-12 and IL-10 cytokines production and a significant increase of natural killer (NK) activity, which predisposes to an active response to viral infections and neoplastic transformations.
authors.affiliation: Clinica Pediatrica, Dipartimento di Scienze Pediatriche, Università degli Studi di Pavia.
authors.forename: C
authors.initials: C
authors.lastname: Valsecchi
authors.forename: A
authors.initials: A
authors.lastname: Marseglia
authors.forename: A
authors.initials: A
authors.lastname: Ricci
authors.forename: L
authors.initials: L
authors.lastname: Montagna
authors.forename: M
authors.initials: M
authors.lastname: Leone
authors.forename: G L
authors.initials: GL
authors.lastname: Marseglia
authors.forename: A M
authors.initials: AM
authors.lastname: Castellazzi
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002648:Child; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy / Q000276:immunology; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology*; D019557:Dermatitis, Perioral / Q000188:drug therapy* / Q000276:immunology*; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D007778:Lactobacillus; D008213:Lymphocyte Activation; D008297:Male; D019936:Probiotics / Q000008:administration & dosage*; D011446:Prospective Studies; D012220:Rhinitis / Q000188:drug therapy / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D016753:Interleukin-10; D018664:Interleukin-12